Objective. The objective of this study is to assess whether genetic functional variants of disintegrin and metalloprotease 33 (ADAM33) are associated with susceptibility to systemic lupus erythematosus (SLE) in a Korean population. Methods. We previously identified 48 single nucleotide polymorphisms (SNPs) in ADAM33. Six SNPs were selected with regard to the linkage disequilibrium pattern. An association study of ADAM33 was conducted in 190 patients with SLE and 469 control subjects. SNPs were genotyped using the TaqMan Real-time polymerase chain reaction method, and haplotype analyses of related variants were performed. Results. All SNPs were in Hardy-Weinberg equilibrium. Significant associations were found between the ADAM33 polymorphisms and SLE at rs2787094 (adjusted odds ratio 
INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease characterized by the production of autoantibodies to multiple nuclear antigens [1] . Epidemiological data on the sibling risk ratio, familial aggregation of SLE, and the disease concordance rate in twins all support a genetic component to the occurrence of SLE [2] . The pathological hallmarks of SLE are altered immune responses to autoantigens with autoantibody production and subsequent tissue injury mediated by deposition of immune complexes. CD4
＋ T cells are critical drivers of the B-cell-dependent auto-antibody response by producing co-stimulatory signals and cytokines [3] . The disintegrin and metalloprotease 33 (ADAM33) gene has been identified and characterized in mice and humans [4, 5] . ADAM33 maps to human chromosome 20p13 and encodes an open reading frame of 2,442 bp consisting of 22 exons. The membrane-anchored proteins of the ADAM gene family possess a unique domain structure containing not only disintegrin and a metalloprotease domains [6, 7] but also a signal sequence prodomain, a catalytic domain, a cysteine-rich domain, an epidermal-growth-factor like domain, and a cytoplasmic domain [8, 9] . These ADAM gene family domains have been suggested to be involved in adhesive interactions, cell fusion, and proteolysis in numerous biological processes, including myoblast fusion, neurogenesis, sperm maturation, and protein-ectodomain shedding of cell surface proteins such as cytokines [10] [11] [12] . The ADAM33 gene is expressed in lung fibroblasts and heart and bronchial smooth muscles and is associated with asthma, chronic obstructive pulmonary disease, and bronchial hyper-responsiveness [13] [14] [15] , where Th2 cytokines play a key role in the pathogenesis of the disease [16] . Th2 cells are also involved in SLE pathogenesis [17] [18] [19] . Th2 cytokines including interleukin (IL) 10 and IL13 are upregulated in patients with SLE due to aberrant DNA methylation of the CD4 ＋ T cell promoter regions, thereby contributing to activate the humoral immune machinery and trigger lupus disease activity [20] . Therefore, we hypothesized that ADAM33 single nucleotide polymorphisms (SNPs) would be associated with susceptibility to SLE.
In our previous study, we reported the ADAM33 polymorphic sites by scanning the entire gene sequence, including the promoter region, by direct sequencing. We found 48 genetic variants in ADAM33, among which six SNPs were genotyped in patients with SLE, healthy subjects, and patients with rheumatoid arthritis (RA) (n= 1,149). Herein, we investigated whether there were associations between ADAM33 polymorphisms and susceptibility to SLE in a Korean population.
MATERIALS AND METHODS

Study population and clinical evaluation
The study population consisted of 190 unrelated consecutive patients with SLE who fulfilled the American College of Rheumatology (ACR) 1987 classification criteria for SLE [21] , 490 unrelated patients with RA who satisfied the ACR classification criteria for RA [22] as a disease control, and 469 healthy controls who had received comprehensive medical testing. All subjects were Koreans recruited from Eulji University Hospital, Chonnam University Hospital, and Wonkwang University Hospital. The mean age of the patients with SLE was 36.3 years, that of the patients with RA was 38.7 years, and that of the control subjects was 38.3 years. The patient characteristics are shown in Table  1 . The study protocol was approved by the institutional review board at Eulji University Hospital, and venous blood samples and records were obtained after receiving written informed consent.
SNP selection
Six SNPs in the ADAM33 gene, including three exonic SNPs (rs528557, rs2280090, and rs2280091) and two intronic SNPs (rs554743 and rs3918395) located in the 3' region near the SNPs (rs2787094) were selected based on a previous study [23] . All SNPs were studied correlation with asthma in European and Asian [13] , especially rs2280091 was associated with bronchial hyper responsiveness in Korean asthmatics [24] .
Autoantibodies
The presence of antinuclear antibody was determined by immunofluorescence using the Hep-2 cell line. Anti-ribonucleoprotein (RNP) antibody and anti-Sm antibody were detected by Alegria Ⓡ test strip (Orgentec GmbH, Mainz, Germany). Anti-Sjögren's syndrome-related antigen A (SSA)/Ro and anti-Sjögren's syndrome-related antigen A (SSB)/La antibody were detected by autoimmune autoimmune EIA Anti-SS-A/Ro, SS-B/Ra test (Bio-Rad Laboratories, Hercules, CA, USA). Hematologic disorder was defined according to the ACR criteria; hemolytic anemia with reticulocytosis, leukopenia (＜4,000/mm were defined by the ACR criteria [25] .
Anti-phospholipid antibodies
The presence of anti-cardiolipin antibody (aCL; immunoglobulin [Ig] G ＞15 IgG phospholipid units, IgM＞ 10 IgM phospholipid units; IncStar, Stillwater, MN, USA), lupus anticoagulant (LAC; partial thromboplastin time or Russell's viper venom time with mix), and anti-β 2 glycoprotein I antibody (anti-β2GPI; QUANTA Lite β 2GPI screen, INOVA Diagnostics Inc., San Diego, CA, USA) was tested in sera or plasma obtained from the study subjects. The three antiphospholipid antibodies (aCL, LAC, and anti-β2GPI) were classified into antibody-positive and antibody-negative groups based on the manufacturer's protocols.
ADAM33 gene genotyping
Genomic DNA was isolated from peripheral blood samples with the G-Spin Blood kit (iNtRON, Daejeon, Korea), and the DNA samples were stored at 4 o C until use. The ADAM33 SNP analysis was performed with the real-time polymerase chain reaction (PCR) allelic discrimination TaqMan assay (Applied Biosystems, Foster City, CA, USA). The real-time PCR analysis was carried out in a total volume of 10 μL with 10 ng genomic DNA, 1 pmol gene specific forward and reverse primers in 1× TaqMan and 2× Universal PCR Master Mix (Applied Biosystems). Real-time PCR was performed using an ABI 7900HT Real-time PCR System (Applied Biosystems) according to the manufacturer's instructions and analyzed with SDS 2.3 software (Applied Biosystems).
Statistical analysis
Chi-square tests were used to estimate the HardyWeinberg equilibrium (HWE). Linkage disequilibrium (LD) analyses were conducted by pairwise comparison of biallelic loci, and the haplotype frequencies of the ADAM33 gene polymorphisms for multiple loci were estimated using gPLINK software ver. 1.06 (http://pngu. mgh.harvard.edu/purcell/plink). Logistic regression analyses were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). The Bonferroni correction (p＜0.05 divided by the number of SNPs analyzed) was used to account for multiple testing.
RESULTS
Six ADAM33 polymorphisms were genotyped in the 190 SLE, 490 RA, and 469 control subjects. The basic clinical characteristics of the patients with SLE and controls are summarized in Table 1 . Each group was selected for similar age, but the proportion of females in the SLE group was higher than that in the control group. We compared the genotype frequencies between patients with SLE and controls. The minor allele frequencies of the six polymorphisms are summarized in Table 2 . All genotype distributions of control subjects were consistent with those expected from the HWE (all p＞0.05). The results of the association between the ADAM33 polymorphisms and SLE risk are shown in Table 3 . Significant allelic differences were observed in the rs2787094 SNPs of the ADAM33 gene between the case and control groups. G alleles at rs2787094 (OR 1.88, 95% CI 1.00 to 3.54; p＜0.0001) resulted in an increased risk for SLE. The recessive rs2787094 model (CC/CG＋GG) was significantly associated with SLE risk (OR 2.09, 95% CI 1.60 to 5.26; p=0.000) after Bonferroni correction for the 6 SNPs analyzed. We further investigated the same polymorphic sites in patients with RA. However, we found no association between the ADAM33 SNPs and susceptibility to RA (Table 3) .
Next, we conducted a subgroup analysis in patients with SLE to determine whether the ADAM33 polymorphisms were associated with the development of any specific SLE Tables 4 and 5 ).
The LD values between each pair of ADAM33 SNPs are presented in Figure 1 . A one haplotype block was defined in our analysis. A haplotype analysis was performed with the six SNPs, and the 10 haplotypes were analyzed. However, no significant differences were observed between the case and control groups.
DISCUSSION
ADAM33 has been identified as an asthma susceptibility factor using a positional cloning strategy [13, 14] . SLE is a disease of unclear etiology and is characterized by a pathogenic autoantibody-related reaction to various organs and tissues. Individual differences in the risk for SLE are mainly genetic and are further modified by environmental exposure and/or chance events experienced by the patient [26] . We found an association between susceptibility to SLE and the ADAM33 SNPs in this study. The female sex ratio of SLE patients is higher than male, about 20:1, so we conducted sex and age adjusted logistic regression analysis. One SNP showed a significant difference between patients with SLE and the control group. This association was expected, as SLE is a Th2 dominant disease.
In contrast, RA is considered a Th1 dominant disease, suggesting that the immunological process is dominated by interferon-γ-secreting CD4 ＋ T cells [27] . Therefore, we found no association between the ADAM33 SNPs and RA.
Stimulation of Th2 cytokines, such as IL-4 and IL-13, increases ADAM33 mRNA expression in lung fibroblasts [16] . IL-4 increases the number of splenic B cells by increasing net migration of circulating B cells to the spleen and by increasing splenic B cell survival [28] . An altered B cell subset in peripheral blood has also been found in patients with SLE who have an increase in the number of immature transitional B-cells, memory B-cells, plasmablasts, and circulating plasma cells that spontaneously produce autoantibodies [29] [30] [31] [32] . We observed a significant association between ADAM33 rs554743 and the presence of IgM aCL in the subtype analysis of patients with SLE stratified by disease-related phenotype. IgM aCL was first identified in association with SLE [33] . IgM aCL is associated with various infections or could be an epiphenomenon during thrombotic events. Our present study had several limitations. First, we analyzed a relatively small number of patients with SLE compared to those of RA and control in a Korean population. The pathogenesis of SLE is highly complex and involves both the genetic background and environmental conditions of patients. Conducting this study with a specific ethnicity of subjects made it difficult to interpret the data. This problem can be overcome in future studies by using replicate groups from other regions of Korea and other ethnic groups.
Second, we did not examine the functional aspects of ADAM33 SNPs. Further study regarding to the functional role of ADAM33 SNPs on the pathogenesis of lupus should be conducted. Our data reveal the association between ADAM33 and susceptibility to SLE. Further investigations assessing the functional role of ADAM33 in patients with SLE will be helpful to clarify the etiology of SLE.
CONCLUSION
We identified 6 SNPs of ADAM33 gene in Korean SLE patients and healthy controls. We demonstrated that ADAM33 polymorphisms are significantly associated with susceptibility to SLE and development of clinical disease manifestation in a Korean population. Investigation on ADAM33 in other ethnic groups and larger population of SLE patients are necessary in the future to further elucidate the pathogenesis of SLE with regard to the current results.
